Oneness Biotech, also known as 合一生技, is a pioneering biotech company established in 2008 and approved by the government as a biopharmaceutical company. It went public on September 23, 2011, under the stock code 4743. In 2020, Oneness Biotech became a constituent stock of the MSCI Global Standard Index.

The company is dedicated to addressing unmet medical needs globally by developing innovative drugs. With a global perspective, Oneness Biotech carefully selects areas for new drug development, explores the mechanisms of drugs and diseases, and utilizes its independent research and development technologies to compete with international pharmaceutical companies. Its focus is on creating maximum value through science and innovation.

Oneness Biotech offers a range of cutting-edge products and services. These include ON101, a groundbreaking new medicine for promoting chronic wound healing in diabetic foot ulcers; FB825, a treatment for atopic dermatitis and allergic asthma; FB704A, an innovation for severe asthma; OB318, a drug for liver cancer treatment; FB918, a treatment for asthma; and SNS812, an innovative small nucleic acid drug for treating coronavirus pneumonia (COVID-19). Join Oneness Biotech, a company committed to developing new drugs and caring for lives.

It offers a thriving business, an excellent professional team, a warm corporate culture, and a conducive work environment. Discover more about their remarkable contributions in the field of biotechnology